Dr. Shalini Shenoy, M.D.

About Shalini Shenoy, M.D.

Education:

• Obtained MD (Doctor of Medicine) from Washington University School of Medicine, St. Louis, MO.
• Completed Residency in Internal Medicine at Washington University School of Medicine.
• Undertook Fellowship in Hematology and Oncology at Washington University School of Medicine.

Experience:

• Specializes in hematology and oncology at the Siteman Cancer Center.

Area of expertise

Affiliated Hospitals

Washington University School Of Medicine

St-Louis Children's Hospital

Clinical Trials Shalini Shenoy, M.D. is currently running

Extended vs Short-Term Abatacept Dosing

for Graft-versus-Host Disease

This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant.

Recruiting0 awards Phase 2

CBL0137

for Cancer

This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.

Recruiting1 award Phase 1 & 213 criteria

More about Shalini Shenoy, M.D.

Other Doctors you might be interested in

Frequently asked questions